Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Genprex ( (GNPX) ) just unveiled an update.
On June 24, 2025, Genprex announced positive preclinical results for its diabetes gene therapy candidate, GPX-002, presented at the 2025 American Diabetes Association Scientific Sessions. The research demonstrated that GPX-002 can induce transdifferentiation of alpha cells into insulin-secreting beta-like cells in animal models, improving glucose control without the need for immunosuppression. The study also highlighted the need for extended immunosuppression to prevent anti-viral immunity in non-human primates, with ongoing evaluations of viral efficacy after six months of immunosuppression.
The most recent analyst rating on (GNPX) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on Genprex stock, see the GNPX Stock Forecast page.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for diseases such as diabetes and cancer. The company’s primary product candidates include GPX-002, a gene therapy drug aimed at treating diabetes by converting alpha cells into insulin-producing beta-like cells.
Average Trading Volume: 4,455,353
Technical Sentiment Signal: Sell
Current Market Cap: $7.66M
For an in-depth examination of GNPX stock, go to TipRanks’ Overview page.